DNDi aims to deliver:
- A solid first-line “4-in-1” fixed-dose combination of abacavir/lamivudine/lopinavir/ritonavir for infants and young children under three years of age
- Immediate introduction of the US FDA approved “2-in-1” LPV/r pellets, to replace high-alcohol syrups, before the availability of better-adapted 4-in-1 products.
The current paediatric HIV portfolio includes:
For more details on each project, see DNDi‘s Global Portfolio